Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees
Executive Summary
FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003